Nevan Elam Biography and Net Worth

Director of Savara

Mr. Elam has served as a member of Savara’s Board of Directors since February 2009. He is currently a member of the Board of Directors and the President and Chief Executive Officer of Rezolute, Inc., a biopharmaceutical company focused on developing therapies for metabolic diseases with serious unmet needs. Prior to his tenure at Rezolute, Mr. Elam held senior executive roles within the pharmaceutical industry, including Senior Vice President and Head of the Pulmonary business unit of Nektar Therapeutics and President and Chief Executive Officer of a European medical device company. Earlier in his career, Mr. Elam was Co-Founder and Chief Financial Officer of E2open, Inc. and a partner in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati, P.C. Mr. Elam holds a J.D. from Harvard Law School and a B.A. from Howard University.

What is Nevan C. Elam's net worth?: The estimated net worth of Nevan C. Elam is at least $515.47 thousand as of March 27th, 2025. Elam owns 224,119 shares of Savara stock worth more than $515,474 as of July 10th. This net worth estimate does not reflect any other investments that Elam may own. Learn More about Nevan C. Elam's net worth.
How old is Nevan C. Elam?: Elam is currently 49 years old. There are 7 older executives and no younger executives at Savara. Learn More on Nevan C. Elam's age.
How do I contact Nevan C. Elam?: The corporate mailing address for Elam and other Savara executives is 6836 Bee Cave Road Building III Suite 200, AUSTIN TX, 78746. Savara can also be reached via phone at 512-614-1848 and via email at [email protected]. Learn More on Nevan C. Elam's contact information.
Has Nevan C. Elam been buying or selling shares of Savara?: Nevan C. Elam has not been actively trading shares of Savara during the last ninety days. Most recently, Nevan C. Elam sold 93,843 shares of the business's stock in a transaction on Thursday, December 28th. The shares were sold at an average price of $4.71, for a transaction totalling $442,000.53. Following the completion of the sale, the director now directly owns 22,500 shares of the company's stock, valued at $105,975. Learn More on Nevan C. Elam's trading history.
Who are Savara's active insiders?: Savara's insider roster includes Badrul Chowdhury (Insider), Nevan Elam (Director), Richard Hawkins (Director), David Lowrance (CFO), Joseph Mccracken (Director), Matthew Pauls (CEO), Raymond Pratt (Insider), and David Ramsay (Director). Learn More on Savara's active insiders.
Are insiders buying or selling shares of Savara?: In the last twelve months, Savara insiders bought shares 3 times. They purchased a total of 78,225 shares worth more than $178,179.00. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 54,702 shares worth more than $181,063.62. The most recent insider tranaction occured on June, 20th when Director Richard J Hawkins bought 48,225 shares worth more than $98,379.00. Insiders at Savara own 5.3% of the company. Learn More about insider trades at Savara.
Information on this page was last updated on 6/20/2025.

Nevan C. Elam Insider Trading History at Savara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/28/2023	Sell	93,843	$4.71	$442,000.53	22,500

Nevan C. Elam Buying and Selling Activity at Savara

Savara Company Overview

Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.

Today's Range

Now: $2.30

$2.29

$2.39

50 Day Range

MA: $2.51

$1.94

$3.40

2 Week Range

Now: $2.30

$1.89

$5.11

Volume

468,667 shs

Average Volume

1,274,796 shs

Market Capitalization

$397.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.31

Nevan Elam Biography and Net Worth

What is Nevan C. Elam's net worth?

How old is Nevan C. Elam?

How do I contact Nevan C. Elam?

Has Nevan C. Elam been buying or selling shares of Savara?

Who are Savara's active insiders?

Are insiders buying or selling shares of Savara?